Cargando…

Boosting NAD(+) for the prevention and treatment of liver cancer

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We...

Descripción completa

Detalles Bibliográficos
Autor principal: Djouder, Nabil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905329/
https://www.ncbi.nlm.nih.gov/pubmed/27308492
http://dx.doi.org/10.1080/23723556.2014.1001199
_version_ 1782437248849936384
author Djouder, Nabil
author_facet Djouder, Nabil
author_sort Djouder, Nabil
collection PubMed
description Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC.
format Online
Article
Text
id pubmed-4905329
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49053292016-06-15 Boosting NAD(+) for the prevention and treatment of liver cancer Djouder, Nabil Mol Cell Oncol Commentary Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide yet has limited therapeutic options. We recently demonstrated that inhibition of de novo nicotinamide adenine dinucleotide (NAD(+)) synthesis is responsible for DNA damage, thereby initiating hepatocarcinogenesis. We propose that boosting NAD(+) levels might be used as a prophylactic or therapeutic approach in HCC. Taylor & Francis 2015-02-03 /pmc/articles/PMC4905329/ /pubmed/27308492 http://dx.doi.org/10.1080/23723556.2014.1001199 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Commentary
Djouder, Nabil
Boosting NAD(+) for the prevention and treatment of liver cancer
title Boosting NAD(+) for the prevention and treatment of liver cancer
title_full Boosting NAD(+) for the prevention and treatment of liver cancer
title_fullStr Boosting NAD(+) for the prevention and treatment of liver cancer
title_full_unstemmed Boosting NAD(+) for the prevention and treatment of liver cancer
title_short Boosting NAD(+) for the prevention and treatment of liver cancer
title_sort boosting nad(+) for the prevention and treatment of liver cancer
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905329/
https://www.ncbi.nlm.nih.gov/pubmed/27308492
http://dx.doi.org/10.1080/23723556.2014.1001199
work_keys_str_mv AT djoudernabil boostingnadforthepreventionandtreatmentoflivercancer